Ignite Creation Date:
2025-12-24 @ 9:06 PM
Ignite Modification Date:
2026-02-22 @ 7:03 PM
Study NCT ID:
NCT02340104
Status:
COMPLETED
Last Update Posted:
2017-06-01
First Post:
2015-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare how much baricitinib (study drug) gets into the blood stream when it is given as a single dose (in tablet form) and as an intravenous infusion (injection given directly into a vein via a small needle). Each participant in the study will make four visits to the investigator site over the course of about 6 weeks.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I4V-MC-JAGM | OTHER | Eli Lilly and Company | View |